Citigroup analyst Joanne Wuensch made the sharpest single move of the day. She cut her target on BSX from $87 to $70 — a 20% reduction — while keeping a Buy rating. That's a notable gap between the bullish call and the revised price target. Boston Scientific carries a $75 billion market cap.
Wuensch also trimmed targets across medtech. PODD fell to $165 from $175. DXCM bucked the trend. Citi raised its target there to $84 from $79, maintaining a Buy on the diabetes device maker.
DLTR had a positive day with analysts. Consensus target prices edged up to $120. The discount retailer saw broad-based target increases as traders watch for a consumer spending resilience story. Short interest sits at 7.4% of free float.
HAS moved the other way. Hasbro's consensus target slipped to $113.53 from $113.80. Analyst sentiment leans heavily sell-side, with 12 sell ratings versus just 0 buys.
CRM saw Citi's Tyler Radke cut his target from $188 to $187 — a marginal move but a downward signal on the CRM giant heading into a busy software earnings season.
A (Agilent Technologies) received the day's only visible upgrade, pushing consensus slightly more bullish.
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
